Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum DSM 32947
- Development stage
- Preclinical
- Lead developer
- BioGaia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum DSM 32947 (also known as BG-L47) is a probiotic bacterial strain isolated from infant feces and developed by BioGaia AB as a live biotherapeutic product. The strain is characterized by its high tolerance to gastric acid and bile, as well as its ability to adhere to human intestinal mucus. It possesses a broad metabolic capacity for degrading various carbohydrates and fibers. DSM 32947 has been shown to stimulate the growth of Limosilactobacillus reuteri DSM 17938 and induce the production of therapeutic microvesicles by other bacteria. Preclinical research has demonstrated its potential to increase bone mineral density, suggesting its utility in managing bone health conditions such as osteoporosis.
- Brand names
- BG-L47BG-L-47BG-L 47
- Other names
- Bifidobacterium longum subspecies longum DSM 32947
Beyond the preview
Go deeper on bifidobacterium longum DSM 32947.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum DSM 32947.